Illustration of a biodegradable device repairing a damaged spinal cord, symbolizing nerve regeneration and restored function.

Can This Breakthrough Bio-Device Repair Spinal Cord Damage?

Reese Marlowe in Health & Wellness November 2026 • 4 min read.

"New research explores the potential of a biodegradable device containing peripheral nerve grafts and FGF1 to regenerate damaged spinal cords and restore motor function."

Spinal cord injuries (SCI) represent a significant and enduring challenge in modern neuroscience. While numerous strategies have shown promise in preclinical studies, translating these into effective clinical treatments remains difficult. Researchers are constantly exploring novel approaches to not only mitigate the secondary damage that occurs immediately post-injury but also promote regeneration of damaged neural pathways.

One such promising approach involves the use of peripheral nerve grafts (PNGs). These grafts act as a scaffold, guiding regenerating nerve fibers across the injury site. When combined with acidic fibroblast growth factor (FGF1), a protein known to promote nerve growth and survival, the potential for functional recovery is significantly enhanced. However, successful implementation of this strategy hinges on the precise placement of these PNGs, a challenge that has spurred the development of innovative delivery methods.

Now, scientists are exploring a groundbreaking solution: a biodegradable device that precisely positions PNGs and delivers FGF1 directly to the injury site. This innovative approach aims to overcome previous limitations and offer a more effective and translatable treatment for spinal cord injuries.

AI Search Multiple angles on this topic

Standard Approach

Current Treatment Approaches

Research into spinal cord injury treatment focuses on reducing long-term effects by inhibiting scar formation and enhancing regeneration through stem cells, with or without growth factors. Induced pluripotent stem cells show promise for autologous use, and clinical trials have confirmed their safety. Reviews emphasize that repair remains difficult because spinal cord injury involves complex pathological mechanisms and substantial barriers to neural and axonal regeneration.

History

From Fatalism to Treatment

The historical management of spinal cord injury has shifted from viewing the condition as inevitably fatal to considering it treatable, although not yet curable. This evolution included continuing debates over whether treatment was appropriate and when surgical intervention should occur. The historical record also describes significant advances developed during military conflicts, while earlier experimental work linked corticospinal regeneration into lumbar gray matter with locomotor recovery after complete spinal cord transection and repair.

The Science Behind the Spinal Cord Repair Breakthrough

Illustration of a biodegradable device repairing a damaged spinal cord, symbolizing nerve regeneration and restored function.

The study, published in Restorative Neurology and Neuroscience, details the development and testing of this novel biodegradable device. Researchers at the Karolinska Institute in Stockholm, Sweden, led by Jonathan Nordblom and Mikael Svensson, designed the device to address the challenges associated with traditional PNG implantation.

The core innovation lies in the device's ability to provide structural support for the PNGs while simultaneously delivering FGF1, a growth factor crucial for nerve regeneration. The device is constructed from calcium sulphate, a biocompatible material that slowly degrades over time, eliminating the need for surgical removal and minimizing long-term complications within the central nervous system (CNS).

Peripheral Nerve Grafts (PNGs): Act as a physical bridge, guiding regenerating axons across the damaged spinal cord segment.
Acidic Fibroblast Growth Factor (FGF1): A potent growth factor that promotes nerve cell survival, proliferation, and axon extension.
Biodegradable Device: Provides structural support for the PNGs, ensures precise placement, and allows for controlled release of FGF1 directly at the injury site.
Calcium Sulphate Composition: Guarantees biocompatibility and gradual degradation of the device, minimizing the risk of long-term complications.

AI Search Multiple angles on this topic

Latest Research

aFGF Nanodelivery in Mice

A PubMed-indexed study reported that aFGFND significantly improved motor-function recovery in mice compared with free aFGF. The authors stated that aFGFND could provide a new avenue for treating central nervous system diseases. Because the reported comparison was conducted in mice, the finding represents preclinical evidence rather than an established human treatment.

Counterpoints

Preclinical Evidence Limits

A study investigated low-energy extracorporeal shock wave therapy in a rat spinal cord injury model. Its methods examined locomotor function, tissue regeneration, inflammation, and mitochondrial function. These model-based investigations can assess several biological and functional outcomes, but the source describes an experimental rat study rather than confirmed clinical effectiveness in people.

The study involved creating a spinal cord resection injury in rats, followed by implantation of the biodegradable device containing PNGs, with or without FGF1. Over several weeks, the animals were assessed using a combination of behavioral testing (BBB score), electrophysiology (motor evoked potentials or MEPs), and immunohistochemistry to evaluate the extent of nerve regeneration and functional recovery.

Looking Ahead: What This Means for Future Spinal Cord Injury Therapies

This research represents a significant step forward in the development of effective therapies for spinal cord injuries. The biodegradable device offers a promising platform for delivering targeted regenerative therapies directly to the injury site. While further research is needed to optimize the device design and FGF1 delivery, these findings pave the way for future clinical trials and ultimately, improved outcomes for individuals living with spinal cord injuries.

Biomaterial combinations compared with injury-only controls

1.6The same comparison found axonal regeneration 1.6 standard deviations higher than in injury-only controls.^[1]

Experimental gains alongside human recovery benchmarks

In complete thoracic injuries, registry data cited in the sources reported AIS conversion in 15.6% of cases by 24 weeks; a separate NACTN report gave a 14.3% conversion rate. These figures describe natural-history outcomes, not outcomes from a biomaterial intervention.^[2]

Clinical guidance also notes spontaneous improvement of about 10 motor points during the first year for people with cervical AIS A injuries. The different injury location and measure mean this is context for interpreting recovery, not a direct comparison with locomotor or axonal outcomes in experimental work.^[3]

A review of clinical biomaterial use reports some improvements in trials but says published large-scale studies with significant positive outcomes do not support routine use. This contrasts with the positive pooled experimental results and underscores that model-based gains have not established broad clinical effectiveness.^{[1] [4]}

A clinical trial of SC0806 found only a tendency toward temporary pain reduction in questionnaires, without consistent benefits on other measurements; its Phase 1/2 study was then terminated. This illustrates that promising regenerative approaches can face a different test in people than in experimental models.^[5]

What translation to people still has to resolve

How much do differences in lesion size and location between people and common animal models alter whether a regenerative intervention succeeds?^[6]
Can studies distinguish intervention effects from spontaneous neurological improvement, given that recovery can occur in some injury groups without a regenerative treatment?^{[2] [3]}
How much confidence should be placed in reported benefits when reporting bias and limited transparency may shape the evidence base?^{[6] [7]}
Would a clinical efficacy result remain convincing with a placebo comparison, given that one trial's lack of a placebo group limited conclusions about effectiveness?^[3]

Sources

Effectiveness of biomaterial-based combination strategies for spinal cord repair – a systematic review and meta-analysis of preclinical literature (pmc.ncbi.nlm.nih.gov)
Natural history of neurological improvement following complete (AIS A) thoracic spinal cord injury across three registries to guide acute clinical trial design and interpretation (pmc.ncbi.nlm.nih.gov)
Advancements in neuroregenerative and neuroprotective therapies for traumatic spinal cord injury (www.frontiersin.org)
The Role of Biomaterials in Peripheral Nerve and Spinal Cord Injury: A Review (pmc.ncbi.nlm.nih.gov)
Regenerative treatment of complete Traumatic Spinal Cord injury with a surgical implantation of a biodegradable device with FGF1 and nerve grafts | H2020 | CORDIS | European CommissionLog inEnglishSea (cordis.europa.eu)
Challenges in Translating Regenerative Therapies for Spinal Cord Injury. (pubmed.ncbi.nlm.nih.gov)
Evaluation of spinal cord injury animal models (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

What is a peripheral nerve graft (PNG) and why is it used in spinal cord injury treatment?

A peripheral nerve graft (PNG) acts as a scaffold to guide regenerating nerve fibers across the injury site in the spinal cord. It's crucial because the spinal cord's ability to naturally regenerate is limited, and the PNG provides a physical pathway for nerve axons to regrow across the damaged area. The implications of this approach are significant, as it offers a way to overcome the body's natural barriers to spinal cord repair, potentially restoring lost motor and sensory functions.

What is acidic Fibroblast Growth Factor (FGF1), and what role does it play in helping to repair spinal cord damage?

Acidic Fibroblast Growth Factor (FGF1) is a protein that promotes nerve cell survival, proliferation, and axon extension. In spinal cord injury treatment, FGF1 is important because it enhances the regenerative capacity of damaged nerves. The presence of FGF1 can significantly improve the effectiveness of peripheral nerve grafts (PNGs), leading to better functional recovery. However, FGF1 alone is not sufficient; it needs to be delivered in a targeted manner, often in conjunction with a structural support system.

What is the biodegradable device and how does it improve spinal cord regeneration?

The biodegradable device is designed to provide structural support for peripheral nerve grafts (PNGs) and ensure precise placement at the injury site, while also allowing for controlled release of acidic Fibroblast Growth Factor (FGF1). Its importance lies in overcoming the limitations of traditional PNG implantation techniques. By degrading over time, it minimizes the risk of long-term complications within the central nervous system (CNS). The implications of using a biodegradable device include reduced need for additional surgeries and a more targeted approach to drug delivery.

Why is the biodegradable device made of calcium sulphate?

Calcium sulphate is used in the biodegradable device because it is a biocompatible material that slowly degrades over time within the body. This biocompatibility minimizes the risk of adverse reactions or rejection by the body's immune system. The gradual degradation of calcium sulphate eliminates the need for surgical removal of the device, further reducing the potential for complications in the central nervous system (CNS). The implications are significant as it allows for a less invasive and more controlled approach to spinal cord regeneration.

Why combine peripheral nerve grafts (PNGs) with acidic Fibroblast Growth Factor (FGF1)?

The combination of peripheral nerve grafts (PNGs) with acidic Fibroblast Growth Factor (FGF1) offers a synergistic approach to spinal cord repair. The PNGs provide a physical scaffold for nerve regeneration, while FGF1 promotes nerve cell survival and growth. This combined approach is more effective than using either method alone. Precise placement of PNGs, facilitated by a biodegradable device, further enhances the regenerative potential. The combined strategy is important to achieve meaningful functional recovery after spinal cord injury.